Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
Apr 11
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Healthcare Sector Analysis
UpdatedApr 16, 2025
DataAggregated Company Financials
Companies366
- 7D4.9%
- 3M0.09%
- 1Y15.2%
- YTD3.3%
Over the last 7 days, the Healthcare industry has risen 4.9%, driven by gains from Samsung BiologicsLtd of 3.0%. This means that the industry has gained 15% over the past year. Looking forward, earnings are forecast to grow by 32% annually.
Sector Valuation and Performance
Has the South Korean Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 16 Apr 2025 | ₩265.3t | ₩56.1t | ₩1.3t | 18.1x | 199.6x | 4.7x |
| Fri, 14 Mar 2025 | ₩272.1t | ₩55.0t | ₩954.9b | 14.9x | 285x | 4.9x |
| Sun, 09 Feb 2025 | ₩282.5t | ₩54.6t | ₩831.2b | 14.8x | 339.9x | 5.2x |
| Tue, 07 Jan 2025 | ₩262.7t | ₩54.6t | ₩808.0b | 14.4x | 325.1x | 4.8x |
| Thu, 05 Dec 2024 | ₩250.6t | ₩54.4t | ₩787.5b | 13.6x | 318.3x | 4.6x |
| Sat, 02 Nov 2024 | ₩264.5t | ₩53.3t | ₩854.8b | 15.6x | 309.4x | 5x |
| Mon, 30 Sep 2024 | ₩267.9t | ₩53.4t | ₩856.0b | 17.1x | 313x | 5x |
| Wed, 28 Aug 2024 | ₩266.0t | ₩53.3t | ₩949.5b | 15.5x | 280.1x | 5x |
| Fri, 26 Jul 2024 | ₩251.1t | ₩52.3t | ₩750.8b | 16.5x | 334.4x | 4.8x |
| Sun, 23 Jun 2024 | ₩228.8t | ₩53.0t | ₩748.3b | 16.5x | 305.8x | 4.3x |
| Tue, 21 May 2024 | ₩228.6t | ₩52.4t | ₩915.6b | 18.2x | 249.6x | 4.4x |
| Thu, 18 Apr 2024 | ₩223.5t | ₩52.3t | ₩538.5b | 17.3x | 415x | 4.3x |
| Sat, 16 Mar 2024 | ₩237.9t | ₩52.2t | ₩165.1b | 20.8x | 1440.7x | 4.6x |
| Mon, 12 Feb 2024 | ₩220.1t | ₩52.0t | -₩55,498,881,746.00 | 21.3x | -3966.1x | 4.2x |
| Wed, 10 Jan 2024 | ₩231.4t | ₩56.1t | ₩268.5b | 23.8x | 861.8x | 4.1x |
| Fri, 08 Dec 2023 | ₩208.3t | ₩56.1t | ₩284.8b | 22.2x | 731.3x | 3.7x |
| Sun, 05 Nov 2023 | ₩199.5t | ₩56.0t | ₩1.0t | 18x | 194.6x | 3.6x |
| Tue, 03 Oct 2023 | ₩205.1t | ₩56.0t | ₩1.0t | 18.7x | 200.4x | 3.7x |
| Thu, 31 Aug 2023 | ₩215.5t | ₩56.0t | ₩988.6b | 23.3x | 218x | 3.9x |
| Sat, 29 Jul 2023 | ₩208.2t | ₩56.1t | ₩2.1t | 20.6x | 99.6x | 3.7x |
| Mon, 26 Jun 2023 | ₩209.4t | ₩56.3t | ₩2.1t | 20.4x | 99.4x | 3.7x |
| Wed, 24 May 2023 | ₩219.8t | ₩58.1t | ₩3.2t | 20.5x | 69.2x | 3.8x |
| Fri, 21 Apr 2023 | ₩214.7t | ₩58.4t | ₩3.2t | 20.4x | 66.1x | 3.7x |
| Sun, 19 Mar 2023 | ₩205.2t | ₩58.0t | ₩4.3t | 19.4x | 48.2x | 3.5x |
| Tue, 14 Feb 2023 | ₩206.1t | ₩57.8t | ₩4.6t | 18.9x | 44.7x | 3.6x |
| Thu, 12 Jan 2023 | ₩204.9t | ₩58.0t | ₩4.4t | 16.5x | 46.9x | 3.5x |
| Sat, 10 Dec 2022 | ₩209.7t | ₩57.5t | ₩3.9t | 16.6x | 54x | 3.6x |
| Mon, 07 Nov 2022 | ₩206.0t | ₩55.9t | ₩4.0t | 15.2x | 51.3x | 3.7x |
| Wed, 05 Oct 2022 | ₩195.8t | ₩55.7t | ₩4.1t | 15.6x | 47.5x | 3.5x |
| Fri, 02 Sep 2022 | ₩215.8t | ₩56.0t | ₩4.2t | 18.2x | 51.3x | 3.9x |
| Sun, 31 Jul 2022 | ₩226.3t | ₩54.2t | ₩3.9t | 20x | 58.2x | 4.2x |
| Tue, 28 Jun 2022 | ₩210.2t | ₩54.2t | ₩3.9t | 18.4x | 54x | 3.9x |
| Thu, 26 May 2022 | ₩223.0t | ₩52.8t | ₩4.0t | 21.7x | 55.3x | 4.2x |
| Sat, 23 Apr 2022 | ₩222.9t | ₩51.0t | ₩4.0t | 22.5x | 56.1x | 4.4x |
Price to Earnings Ratio
56.1x
Current Industry PE
- Investors are pessimistic on the South Korean Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 200x which is lower than its 3-year average PE of 248x.
- The 3-year average PS ratio of 4.2x is lower than the industry's current PS ratio of 4.7x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 31% per year over the last three years.
- Meanwhile revenues for these companies have grown 3.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare sector?
| KR Market | 6.46% | |
| Healthcare | 4.93% | |
| Healthtech | 19.44% | |
| Medical Equipment | 5.72% | |
| Life Sciences | 4.94% | |
| Pharma | 4.93% | |
| Biotech | 4.44% | |
| Healthcare Services | 2.11% | |
Industry PE
- Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 0.73x.
- It looks like they are confident that earnings will grow faster in the future than they have historically.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 101% over the next 5 years.
- This is roughly in line with its past earnings growth rate.
- In contrast, the Life Sciences industry is expected to see its earnings grow by 18% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A207940 Samsung BiologicsLtd | ₩1.03m | 3.0% +₩2.1t | 31.7% | PE67.9x | |
| A087010 Peptron | ₩160.80k | 43.6% +₩1.1t | 606.8% | PS1188.5x | |
| A196170 ALTEOGEN | ₩380.00k | 5.4% +₩1.0t | 125.8% | PE325.3x | |
| A000100 Yuhan | ₩113.50k | 8.1% +₩637.5b | 63.8% | PE120.4x | |
| A298380 ABL Bio | ₩64.00k | 25.5% +₩630.9b | 190.2% | PS93x |
